Compare · ABT vs NBP
ABT vs NBP
Side-by-side comparison of Abbott Laboratories (ABT) and NovaBridge Biosciences (NBP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and NBP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $151.52B, about 750.4x NBP ($201.9M).
- Both names hit the wire about 4 times in the past 4 weeks.
- ABT has more recent analyst coverage (25 ratings vs 1 for NBP).
- Company
- Abbott Laboratories
- NovaBridge Biosciences
- Price
- -
- -
- Market cap
- $151.52B
- $201.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 1
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
Latest NBP
- SVP, Clinical Development Xu Cong Claire converted options into 9,382 units of Ordinary Shares and sold $13,766 worth of Ordinary Shares (3,494 units at $3.94), increasing direct ownership by 2% to 290,154 units (SEC Form 4)
- NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
- Officer Cao Sean Wuxiong sold $42,584 worth of Ordinary Shares (21,399 units at $1.99), decreasing direct ownership by 38% to 35,073 units (SEC Form 4) to cover taxes
- NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
- Officer Hagler Mark Arnold bought $577,300 worth of Ordinary Shares (230,000 units at $2.51) (SEC Form 4)
- SEC Form 3 filed by new insider Hagler Mark Arnold
- SEC Form 6-K filed by NovaBridge Biosciences
- NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
- Amendment: SEC Form 3 filed by new insider Xu Cong Claire
- SEC Form 6-K filed by NovaBridge Biosciences